| Clinically isolated syndrome
Aubagio vs Gilenya
Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.Deep comparison between: Aubagio vs Fingolimod with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFingolimod has a higher rate of injection site reactions vs Aubagio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fingolimod but not Aubagio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aubagio
Fingolimod
At A Glance
Oral
Daily
Pyrimidine synthesis inhibitor
Oral
Daily
Sphingosine 1-phosphate receptor modulator
Indications
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Clinically isolated syndrome
- Multiple Sclerosis, Secondary Progressive
Dosing
Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome 7 mg or 14 mg orally once daily; may be taken with or without food.
Multiple Sclerosis, Relapsing-Remitting, Clinically isolated syndrome, Multiple Sclerosis, Secondary Progressive 0.5 mg orally once daily for adults and pediatric patients >40 kg; 0.25 mg orally once daily for pediatric patients 10 years of age and older weighing <=40 kg; may be taken with or without food; first-dose monitoring for bradycardia required.
Contraindications
- Severe hepatic impairment
- Pregnancy or females of reproductive potential not using effective contraception
- History of hypersensitivity reaction to teriflunomide, leflunomide, or any inactive ingredient (including anaphylaxis, angioedema, or serious skin reactions)
- Coadministration with leflunomide
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure within the last 6 months
- History or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome without a functioning pacemaker
- Baseline QTc interval >= 500 msec
- Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs
- Hypersensitivity to fingolimod or any excipient in fingolimod capsules
Adverse Reactions
Most common (>=2% above placebo) Headache, increased alanine aminotransferase, diarrhea, alopecia, nausea, paresthesia, arthralgia, neutropenia, hypertension
Serious Hepatotoxicity, bone marrow effects/immunosuppression/infections, hypersensitivity reactions, serious skin reactions, DRESS, cutaneous or mucocutaneous ulcers and impaired wound healing, peripheral neuropathy, increased blood pressure, respiratory effects, pancreatitis (pediatric patients)
Postmarketing Thrombocytopenia, pancreatitis, colitis, drug-induced liver injury, anaphylaxis, angioedema, interstitial lung disease, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS, psoriasis (including pustular and nail), nail disorders, cutaneous or mucocutaneous ulcers, impaired wound healing
Most common (>=10%) Headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, pain in extremity
Serious Bradyarrhythmia, AV block, infections, progressive multifocal leukoencephalopathy, macular edema, liver injury, posterior reversible encephalopathy syndrome, fetal risk, malignancies, hypersensitivity reactions
Postmarketing Hemolytic anemia, thrombocytopenia, cryptococcal infections, HPV infection, seizures including status epilepticus, melanoma, Merkel cell carcinoma, cutaneous T-cell lymphoma, Kaposi's sarcoma, squamous cell carcinoma
Pharmacology
Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme required for de novo pyrimidine synthesis, which may reduce the number of activated lymphocytes in the CNS.
Sphingosine 1-phosphate (S1P) receptor modulator; fingolimod is metabolized to fingolimod-phosphate, which binds S1P receptors 1, 3, 4, and 5 with high affinity, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts, potentially reducing lymphocyte migration into the central nervous system.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aubagio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (4/12)
Fingolimod
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (2/12) · Qty limit (11/12)
UnitedHealthcare
Aubagio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Fingolimod
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Aubagio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Fingolimod
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Multiple Sclerosis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AubagioView full Aubagio profile
FingolimodView full Fingolimod profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.